PLYGF Stock Chart & Stats
$54.12
$0.00(0.00%)
At close: 4:00 PM EDT
$54.12
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$31.50 - $63.99
Previous CloseN/A
Volume16.00
Average Volume (3M)56.00
Market Cap
$1.79B
Enterprise Value$1.63K
Total Cash (Recent Filing)$59.21M
Total Debt (Recent Filing)$139.52M
Price to Earnings (P/E)108.7
Beta-189368.06
Next Earnings
Mar 09, 2027EPS Estimate
0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.43
Shares OutstandingN/A
10 Day Avg. Volume10
30 Day Avg. Volume56
Financial Highlights & Ratios
PEG Ratio-5.17
Price to Book (P/B)2.72
Price to Sales (P/S)2.36
P/FCF Ratio-30.38
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$54.74Price Target Upside1.14% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)1.07
Revenue Forecast (FY)$615.74M
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained top-line growth indicates continued demand for PolyPeptide’s peptide and oligonucleotide CDMO services. Expanding customer programs and commercial manufacturing volumes can support capacity utilization and provide a foundation for longer-term operating recovery.
Improving Operating Cash FlowPositive and improving operating cash flow shows that core operations are generating funding despite reported net losses. This supports ongoing development and manufacturing activity, reduces reliance on external financing, and strengthens resilience through the recovery period.
Specialized CDMO PlatformPolyPeptide combines process development, analytical, quality, regulatory, and cGMP manufacturing services in specialized molecules. This integrated expertise can deepen customer relationships and create switching costs as programs progress from clinical development to commercial supply.
Bears Say
Persistent Net LossesOngoing net losses indicate that the business has not yet converted revenue growth into sustainable shareholder returns. Continued losses can limit internal reinvestment, weaken equity, and increase dependence on operational improvement or external capital.
Margin CompressionThe sharp decline from earlier profitability suggests pressure from cost inflation, underutilized capacity, execution issues, or unfavorable project mix. Margin recovery may require stronger utilization and pricing discipline, making earnings improvement uncertain over the medium term.
Volatile Free Cash FlowNegative and inconsistent free cash flow indicates that investment and working-capital requirements can absorb operating cash generation. This may constrain financial flexibility, particularly while the company remains loss-making and continues expanding or upgrading capacity.
PolyPeptide Group AG News
PLYGF FAQ
What was PolyPeptide Group AG’s price range in the past 12 months?
PolyPeptide Group AG lowest stock price was $31.50 and its highest was $63.99 in the past 12 months.
What is PolyPeptide Group AG’s market cap?
PolyPeptide Group AG’s market cap is $1.79B.
When is PolyPeptide Group AG’s upcoming earnings report date?
PolyPeptide Group AG’s upcoming earnings report date is Mar 09, 2027 which is in 183 days.
How were PolyPeptide Group AG’s earnings last quarter?
PolyPeptide Group AG released its earnings results on Aug 13, 2026. The company reported $0.315 earnings per share for the quarter, beating the consensus estimate of $0.082 by $0.234.
Is PolyPeptide Group AG overvalued?
According to Wall Street analysts PolyPeptide Group AG’s price is currently Undervalued.
Does PolyPeptide Group AG pay dividends?
PolyPeptide Group AG does not currently pay dividends.
What is PolyPeptide Group AG’s EPS estimate?
PolyPeptide Group AG’s EPS estimate is 0.71.
How many shares outstanding does PolyPeptide Group AG have?
Currently, no data Available
What happened to PolyPeptide Group AG’s price movement after its last earnings report?
PolyPeptide Group AG reported an EPS of $0.315 in its last earnings report, beating expectations of $0.082. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PolyPeptide Group AG?
Currently, no hedge funds are holding shares in PLYGF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PolyPeptide Group AG
PolyPeptide Group AG operates globally as a contract development and manufacturing organization (CDMO), specializing in the production of Good Manufacturing Practice (GMP)-grade peptides. These peptides, available in both proprietary and generic forms, are vital for pharmaceutical and biotechnology companies, serving as key ingredients in approved medicines, compounds undergoing clinical development, and generic drug formulations. The company also produces custom research-grade peptides and actively develops neoantigen peptides to support personalized cancer therapies. Its manufacturing expertise extends to peptides used in commercially approved therapeutics, peptide-based generics for human and veterinary applications, and cosmetic peptides. Additionally, PolyPeptide Group AG provides regulatory affairs support services. Founded in 1952 and headquartered in Zug, Switzerland, the company is a subsidiary of Draupnir Holding B.V.
PLYGF Stock 12 Month Forecast
Average Price Target
$54.74
▲(1.14% Upside)
Technical Analysis
Lonza Group Ltd
―
Bachem Holding AG
―
Siegfried Holding AG
―
Sandoz Group Ltd
―
Joincare Pharmaceutical Group Industry Co., Ltd. Sponsored GDR Class A RegS
―
Ownership Overview
―
Insiders
1.30% Mutual Funds
― Other Institutional Investors
94.12% Public Companies and
Individual Investors